LMR Partners’s Cue Biopharma CUE Stock Holding History

LMR Partners’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-488	Closed	-$33K	–	1141
2022 Q3	$33K	Hold	488	–	–	﹤0.01%	1131
2022 Q2	$36K	Buy	+488	New	+$57.1K	﹤0.01%	1189

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's CUE Position: Q4 2022 in Review

LMR Partners sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 488 shares — an estimated $33K sold.

LMR Partners first reported a position in CUE in Q2 2022 and held it in 2 quarters. The position peaked at $36K in Q2 2022. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

LMR Partners reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 488 Cue Biopharma shares in Q4 2022, an estimated $33K.
LMR Partners first reported a position in Cue Biopharma in Q2 2022 and held it in 2 quarters.
LMR Partners's Cue Biopharma position peaked at $36K in Q2 2022.
61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.